BMS signs new $200M licensing deal for CytomX probodies
Bristol-Myers Squibb has signed up for another eight probody drug candidates from CytomX Therapeutics. Probodies are "masked" monoclonal antibodies that become activated when they interact with the tumor microenvironment.